Author:
Talbot George H.,Powers John H.,Hoffmann Steven C.
Funder
National Institutes of Health
NIH
National Institute of Allergy and Infectious Diseases [NIAID]
NIAID
Actelion, Basilea, Bayer, Cubist
The Medicines Company, Merck, Nabriva, Roche, and Tetraphase
Pfizer Inc
Shionogi Pharmaceuticals
Theravance Inc
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Microbiology (medical)
Reference22 articles.
1. US Food and Drug Administration, Center for Drug Evaluation. Guidance for industry. Antibacterial drug products: use of noninferiority trials to support approval. Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070951.pdf . Accessed 15 January 2015.
2. Powers JH , Patrick D , Walton M et al . ISPOR Clinical Outcome Assessment Task Force. Developing and evaluating Clinician-Reported Outcome (ClinRO) assessments of treatment benefit; emerging good measurement practices. Value Health. In press.
3. Clinical Outcome Assessments: Conceptual Foundation—Report of the ISPOR Clinical Outcomes Assessment – Emerging Good Practices for Outcomes Research Task Force
4. Pediatric Patient-Reported Outcome Instruments for Research to Support Medical Product Labeling: Report of the ISPOR PRO Good Research Practices for the Assessment of Children and Adolescents Task Force
5. US Food and Drug Administration, Center for Drug Evaluation. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment, 2013. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071185.pdf. Accessed 15 January 2015.
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献